Discontinued Product

1-BCP (Cat. No. 1048) has been withdrawn from sale for commercial reasons.
Description: Modulates AMPA-mediated responses
Chemical Name: 1-(1,3-Benzodioxol-5-ylcarbonyl)piperidine
Purity: ≥99% (HPLC)
Literature (5)

Biological Activity for 1-BCP

A centrally active selective potentiator of AMPA-mediated responses. Facilitates memory retention in rats.

Technical Data for 1-BCP

M. Wt 233.27
Formula C13H15NO3
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 34023-62-6
PubChem ID 1370
Smiles O=C(N1CCCCC1)C1=CC2=C(OCO2)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for 1-BCP

References are publications that support the biological activity of the product.

Arai et al (1994) A centrally active drug that modulates AMPA receptor gated currents. Brain Res. 638 343 PMID: 7911064

Desai et al (1995) 1-BCP, a memory-enhancing agent, selectively potentiates AMPA-induced [3H]NE release in rat hippocampal slices. Neuropharmacology 34 141 PMID: 7542369

Vanove (1997) Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion. Eur.J.Pharmacol. 332 115 PMID: 9286612

Yamada et al (1998) AMPA receptor activation potentiated by the AMPA modulator 1-BCP is toxic to cultured rat hippocampal neurons. Neurosci.Lett. 249 119 PMID: 9682831

View Related Products by Target

Keywords: 1-BCP, 1-BCP supplier, Modulates, AMPA-mediated, responses, Glutamate, Receptors, iGlur, Ionotropic, AMPA, 1048, Tocris Bioscience

Citations for 1-BCP

Citations are publications that use Tocris products.

Currently there are no citations for 1-BCP.

Reviews for 1-BCP

There are currently no reviews for this product. Be the first to review 1-BCP and earn rewards!

Have you used 1-BCP?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.